Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Postoperativ atrieflimmer etter kirurgisk utskifting av aortaklaffen og påvirkning av statiner

14. november 2026 oppdatert av: Lars Peter Riber

Postoperativ atrieflimmer etter kirurgisk utskifting av aortaklaffen og påvirkningen av statiner – randomisert kontrollert forsøk

Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery.

The focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF).

Our aims are: to investigate the risk of POAF, infection or other complications after SAVR in continuous versus preoperative discontinuous treatment with statins.

The study is a single centre randomized controlled trial with continuance treatment with statin vs. discontinuance (7 to 14 days prior surgery until the 30th post-operative day included), on patients undergoing elective solitary SAVR with bioprosthesis with prior usage of statins the last 3 months and of at least 7 days.

This randomized studies will address 2 separate hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that

  1. Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (<30 days) risk of POAF.
  2. Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (<30 days) and intermediate (<1 year) risk of mortality, MI, stroke and rehospitalisation.

Studieoversikt

Detaljert beskrivelse

Trial Participants:

Enrolment for the study is planned to start February 2022 and continue until 100 patients have been enrolled.

DEFINITION OF POAF:

Postoperative AF (I48) is defined as irregular RR-intervals without a traceable p-wave before each QRS complex during at least 30 seconds or entire 12-lead ECG in symptomatic or asymptomatic patients with no prior history of atrial fibrillation or flutter are considered4. Continuous ECG monitoring (8-lead ward monitor) will recognise AF during the entire hospitalization. Anamnesis, electronic health record (EHR), or confirmatory rhythm strip or 12-lead ECG of AF until 30th postoperative day are also considered.

We will also report the burden of atrial fibrillation, and treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.

Course of action:

Patients undergoing elective surgical aortic valve replacement with bioprosthesis at the Department of Cardiac Surgery at Odense University Hospital will be offered participation in the study.

Potentially eligible patients will be screened according to inclusion/exclusion criteria at the time after eligibility of surgery. This is assessed at a multidisciplinary team (MDT) conference (with attendance of cardiologist, cardiac surgeons and anaesthesiologist) based on clinical evaluation, echocardiographic ultrasound, coronary angiography and lung function test.

Patients eligible to participate in the study will be presented with the information of the study at the time of their out-patient appointment, according to normal routine at Odense University Hospital. At this appointment the patient receives a physical examination and journal record is obtained by a cardiac surgeon (approximately 7 to 14 days prior to planned surgery).

The study-information will be given by one of the participating doctors, while the patient has been informed of the possibility of bringing an assessor of their choice. The information will be delivered in a quiet room blocked to other appointments in the Department of Cardiothoracic Surgery.

During this meeting the patient will be informed of the purpose of this study and the written patient information will be submitted in detail. Patients will be given as much time as wanted after the oral information has been delivered to decide if they wish to participate in the study. Patients will be offered the possibility to call one of the doctors taking part in this study during this time, in case of additional questions. Subjects can leave the study at any time for any reason if they wish to do so, without any consequences.

Signed informed consent will be provided prior to any research procedures. A subject is registered when signed informed consent has been provided and assigned a subject identification code by the computer-generated code. A subject is randomized when a treatment and a randomisation number has been provided. A subject is considered enrolled in the study once the subject is randomized.

Patient data from EHR will be conducted according to study endpoints after signed informed consent is provided. Signed consent gives sponsor and sponsors representatives

Randomization:

Allocation to a numbered treatment pack (continuance or discontinuance of statin therapy) Randomization scheme will be set-up by OPEN data manager with control for beta-blockers and age (60-65, 66-70, 71-80, >80), and then randomization per se will be executed with the use of REDCap.

The following will be recorded at the day of randomization:

  • Conduct information for baseline characteristics
  • Transthoracic Echocardiography measurements

Collect baseline blood sample:

• Troponin, CK-MB, Creatinine, CRP

Commence intervention

Perioperative interventions and outcomes from the day of surgery to the day of discharge:

  • Duration of aortic cross clamp (ACC), extracorporeal circulation (ECC), ventilatory support, intensive care unit stay period, hospital stay period

  • Continue intervention

  • Blood samples:

    • Preoperative: Troponin, CK-MB, Creatinine, CRP, Plasma-Atorvastatin
    • Serial troponin and CK-MB levels: (6, 24, 48, and 96 hours after surgery).
    • Creatinine levels: 48 and 96 hours after surgery.
    • CRP levels: 48 and 96 hours after surgery
  • Monitor ECG by continuous Holter monitoring to commence as soon as possible after surgery and continue up to post-operative day 5 evening

  • Transthoracic Echocardiography on post-operative day 3-5

  • Record fluid intake and output during the first 48 hours following surgery based on IV fluids administration, blood transfusion (if applicable), oral/nasogastric intake, and urine plus surgical drain output

  • Record intraoperative defibrillation, removal of external pacemaker, new PPM/ICD, vasopressors, blood transfusion, surgical re-exploration, renal replacement therapy, beta-blockers, ACEi/ARB, Amiodarone, Digoxin, Diuretics, Calcium channel blockers, Potassium supplements, NSAIDs or steroids, non-study statin, use of nephrotoxic antibiotics, contrast agents or potassium sparing diuretics (Yes/No)

Assessment at/after discharge from hospital:

  • Continue study medications for 30 days after the surgery
  • Phone call on the 30th postoperative day to evaluate symptoms of discomfort compatible with atrial fibrillation
  • At the end of the study, all excess study medication can be returned at the local drugstore for safe disposal
  • Patient data from EHR will be conducted according to study endpoints.

Studietype

Intervensjonell

Registrering (Faktiske)

100

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Odense, Danmark, 5000
        • Odense University Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

60 år til 95 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients undergoing elective solitary SAVR with bioprosthesis
  2. Patients who are in sinus rhythm and not taking any anti-arrhythmic medication, other than beta-adrenergic blocking agents, at the time of surgery
  3. In treatment with HMG-CoA reductase inhibitors in the past 3 months and of at least 7 days
  4. Age >60 years
  5. Willingness and provision of informed consent to be randomized

Exclusion Criteria:

  1. Prior history of atrial fibrillation
  2. Prior history of cardiac surgery
  3. Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit)
  4. Creatinine >200 µmol/L

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Continuance

Continuance prior statin therapy.

Continuance of prior statin therapy

Eksperimentell: Discontinuance

Discontinuance prior statin therapy. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Discontinuance of prior statin therapy

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants with POAF - In-hospital
Tidsramme: In-hospital up to 10 days.

In-hospital POAF assessed by Holter monitoring.

In-hospital up to 10 days.
Number of Participants with POAF - Early
Tidsramme: Early (≤30 days) incidence of POAF

Early assessed by anamnesis and electronic health record (EHR).

Early (≤30 days) incidence of POAF
Duration of POAF in-hospital
Tidsramme: In-hospital

Duration of POAF monitered with continuous ECG monitoring (eight-- lead ward monitor) up to 24 weeks.

In-hospital

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Stroke - Intermediate
Tidsramme: Intermediate (1 year)

Number of patients with stroke in each group.

Intermediate (1 year)
Trans ischemic attack - Early
Tidsramme: Early (≤30 days)

Number of patients with trans ischemic attack in each group.

Early (≤30 days)
Trans ischemic attack - Intermediate
Tidsramme: Intermediate (1 year)

Number of patients with trans ischemic attack in each group.

Intermediate (1 year)
Myocardial infarction - Early
Tidsramme: Early (≤30 days)

Number of patients with Myocardial infarction in each group.

Early (≤30 days)
Myocardial infarction - Intermediate
Tidsramme: Intermediate (1 year)

Number of patients with Myocardial infarction in each group.

Intermediate (1 year)
Permanent pacemaker - Early
Tidsramme: Early (≤30 days)

Number of patients with Permanent pacemaker in each group.

Early (≤30 days)
Permanent pacemaker - Intermediate
Tidsramme: Intermediate (1 year)

Number of patients with Permanent pacemaker in each group.

Intermediate (1 year)
ICD implantation - Early
Tidsramme: Early (≤30 days)

Number of patients with ICD implantation in each group.

Early (≤30 days)
ICD implantation - Intermediate
Tidsramme: Intermediate (1 year)

Number of patients with ICD implantation in each group.

Intermediate (1 year)
Acute kidney injury - Early
Tidsramme: Early (≤30 days)

Number of patients with Acute kidney injury in each group.

Early (≤30 days)
LVEF
Tidsramme: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of LVEF(left ventricular ejection fraction) between groups. Unit: %

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Strain
Tidsramme: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of Strain between groups.Unit: %

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
TAPSE
Tidsramme: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of TAPSE (tricuspid annular plane systolic excursion) between groups. Unit: mm

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Length of stay on ICU
Tidsramme: Day of surgery to the day of discharge from ICU. Up to 52 weeks.

Length of stay on ICU after surgery. Unit: Days

Day of surgery to the day of discharge from ICU. Up to 52 weeks.
Number of Participants with NOAF
Tidsramme: Intermediate (1 year) incidence of NOAF

NOAF assessed by anamnesis and EHR.

Intermediate (1 year) incidence of NOAF
Rate of all-cause mortality - In-hospital
Tidsramme: In-hospital up to 10 days.

Number of deaths in each group.

In-hospital up to 10 days.
Rate of all-cause mortality - Early
Tidsramme: Early (≤30 days)

Number of deaths in each group.

Early (≤30 days)
Rate of all-cause mortality - intermediate
Tidsramme: Intermediate (1 year)

Number of deaths in each group.

Intermediate (1 year)
Myocardial injury - Tn
Tidsramme: After surgery until discharge up to 10 days

Injury assessed by serial Troponin measurements. Unit:ng/l

After surgery until discharge up to 10 days
Myocardial injury - CKMB
Tidsramme: After surgery until discharge up to 10 days

Injury assessed by serial CKMB measurements. Unit: μg/l.

After surgery until discharge up to 10 days
Stroke - Early
Tidsramme: Early (≤30 days).

Number of patients with stroke in each group.

Early (≤30 days).
Length of stay in hospital
Tidsramme: Day of surgery to the day of discharge from the hospital. Up to 52 weeks.

Length of stay in hospital after surgery. Unit: Days

Day of surgery to the day of discharge from the hospital. Up to 52 weeks.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. april 2022

Primær fullføring (Faktiske)

1. oktober 2026

Studiet fullført (Faktiske)

1. oktober 2026

Datoer for studieregistrering

Først innsendt

19. august 2021

Først innsendt som oppfylte QC-kriteriene

29. september 2021

Først lagt ut (Faktiske)

30. september 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • STARC210421_3
  • 2021-002210-13 (EudraCT-nummer)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Data will be available in anonymized form in accordance with GDPR upon reasonable request.

Rules for external researchers to apply for and access data will be laid out towards the end of the study.

IPD-delingstidsramme

TBA

Tilgangskriterier for IPD-deling

TBA

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere